ProteoNic
BV, a
leading provider of premium vector technology and services for efficient
production of biologics, and FyoniBio GmbH, a contract development organization
for biopharmaceuticals, today announced they have entered into a technology
licensing agreement. Under the agreement, FyoniBio gains worldwide,
non-exclusive commercial rights for application of ProteoNic technology in its
proprietary CHOnamite® platform. As a result, FyoniBio’s clients will profit from
extended options for cell line development and significantly reduced cost of
goods for their products. Financial terms of the agreement include milestone
payments to ProteoNic on a per product basis.
ProteoNic’s premium
protein expression technology 2G
UNic™ improves production levels across a range of mammalian cell
types, selection systems and product classes. This is achieved by the combined
effect of novel genetic elements which together boost recombinant protein
production on various levels. The technology increases production levels of
complex proteins which are difficult to produce, including bi-specifics and
fusion proteins as well as levels of products already in the multiple g/L
range. Additionally, 2G UNic™ can be used to boost the performance of other
expression enhancing technologies.
Frank Pieper, CEO of ProteoNic commented: “We are
pleased that we can contribute to achieving the best results for FyoniBio and
its customers. In this arrangement, FyoniBio will play an active role in the
distribution of our premium technology to product developers.”
Lars Stöckl, Managing Director of FyoniBio added: “We
believe in providing the most efficient processes and best solutions to our
customers. By offering ProteoNic’s 2G UNic™ technology in combination with our
own highly efficient cell line platforms, our clients have multiple options to
achieve the best possible outcome”.
No comments:
Post a Comment